Literature DB >> 27456211

Extensive and severe CNS demyelination associated with golimumab therapy.

Elisabeth Maillart1, Caroline Papeix2, Charles Mellerio3,4, Anne Bertrand5, Catherine Lubetzki2, Céline Louapre2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27456211     DOI： 10.1007/s00415-016-8238-5

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  10 in total

Review 1.  New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review.

Authors:  Takumi Matsumoto; Ichiro Nakamura; Ayumi Miura; Gen Momoyama; Katsumi Ito
Journal:  Clin Rheumatol       Date:  2012-11-14       Impact factor: 2.980

Review 2.  Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review.

Authors:  María Cruz Fernández-Espartero; Beatriz Pérez-Zafrilla; Antonio Naranjo; Carmen Esteban; Ana M Ortiz; Juan J Gómez-Reino; Loreto Carmona
Journal:  Semin Arthritis Rheum       Date:  2011-12       Impact factor: 5.532

Review 3.  Neurological adverse events associated with anti-tumor necrosis factor α treatment.

Authors:  Antonio G Tristano
Journal:  J Neurol       Date:  2010-05-22       Impact factor: 4.849

4.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

5.  Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy.

Authors:  C W Cereda; C Zecca; L Mazzucchelli; L Valci; C Staedler; C L Bassetti; C Gobbi
Journal:  Mult Scler       Date:  2012-10-15       Impact factor: 6.312

6.  Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey.

Authors:  Raphaèle Seror; Christophe Richez; Christelle Sordet; Stéphanie Rist; Laure Gossec; Guillaume Direz; Eric Houvenagel; Jean-Marie Berthelot; Christian Pagnoux; Emmanuelle Dernis; Sylvie Melac-Ducamp; Beatrice Bouvard; Caroline Asquier; Antoine Martin; Xavier Puechal; Xavier Mariette
Journal:  Rheumatology (Oxford)       Date:  2013-01-03       Impact factor: 7.580

Review 7.  Autoimmune diseases induced by biological agents: a double-edged sword?

Authors:  Manuel Ramos-Casals; Candido Diaz-Lagares; Maria-Jose Cuadrado; Munther A Khamashta
Journal:  Autoimmun Rev       Date:  2009-10-23       Impact factor: 9.754

Review 8.  Safety of anti-tumor necrosis factor therapies in arthritis patients.

Authors:  Radu M Nanau; Manuela G Neuman
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

10.  Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.

Authors:  Jonathan Kay; Roy Fleischmann; Edward Keystone; Elizabeth C Hsia; Benjamin Hsu; Michael Mack; Neil Goldstein; Jürgen Braun; Arthur Kavanaugh
Journal:  Ann Rheum Dis       Date:  2013-12-16       Impact factor: 19.103
  10 in total
  2 in total

Review 1.  CNS Demyelination with TNF-α Blockers.

Authors:  Elissavet Kemanetzoglou; Elisabeth Andreadou
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

Review 2.  TNFα in MS and Its Animal Models: Implications for Chronic Pain in the Disease.

Authors:  Aislinn D Maguire; John R Bethea; Bradley J Kerr
Journal:  Front Neurol       Date:  2021-12-06       Impact factor: 4.003
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.